Langa-Douglas  was appointed Senior Vice President, Head of North America Operations and President of Novo Nordisk Inc. in March 2017 and was promoted to Executive Vice President, North America Operations and President of Novo Nordisk Inc. in August 2017. In this role, Mr. Langa has full business responsibility for Novo Nordisk’s largest sales region, comprised of the United States and Canada. Prior to his current role, Mr. Langa served as Senior Vice President, Market Access, where he was responsible for securing formulary access with key payer customers for Novo Nordisk brands. The Market Access function at Novo Nordisk covers payer marketing, contract strategy, pricing, and account management for all promoted and in-line brands. Under Mr. Langa’s leadership, the Market Access account executive team has received numerous third-party recognitions for their performance allowing a broad number of patients with chronic diseases to benefit from having access to Novo Nordisk brands. Langa-Douglas  was appointed Senior Vice President, Head of North America Operations and President of Novo Nordisk Inc. in March 2017 and was promoted to Executive Vice President, North America Operations and President of Novo Nordisk Inc. in August 2017. In this role, Mr. Langa has full business responsibility for Novo Nordisk’s largest sales region, comprised of the United States and Canada. Prior to his current role, Mr. Langa served as Senior Vice President, Market Access, where he was responsible for securing formulary access with key payer customers for Novo Nordisk brands. The Market Access function at Novo Nordisk covers payer marketing, contract strategy, pricing, and account management for all promoted and in-line brands. Under Mr. Langa’s leadership, the Market Access account executive team has received numerous third-party recognitions for their performance allowing a broad number of patients with chronic diseases to benefit from having access to Novo Nordisk brands.

Marketing